To include your compound in the COVID-19 Resource Center, submit it here.

GI-6207: Phase I data

An open-label, dose-escalation Phase I trial in 25 patients showed that subcutaneous GI-6207 given

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE